Regulatory Application

AstraZeneca PLC
04 February 2008


                 ASTRAZENECA BIOLOGICS DIVISION, MEDIMMUNE, SUBMITS 

                BIOLOGICS LICENSE APPLICATION TO FDA FOR MOTAVIZUMAB 

              

AstraZeneca PLC announced today that its biologics division, MedImmune, had
submitted a Biologics License Application (BLA) to the U.S. Food & Drug
Administration (FDA) for motavizumab, an investigational monoclonal antibody
(MAb) derived from recombinant DNA technology.



'We expect that this submission will lead to the first new medicine delivered by
MedImmune since we acquired the company in June 2007 and one of three new
filings that we plan to make this year. MedImmune has a well-established
reputation in the prevention of RSV through its existing product, Synagis.
Motavizumab offers the opportunity to build on this knowledge and improve
treatment for a young and vulnerable patient population,' said David Brennan,
Chief Executive Officer, AstraZeneca.



4 February 2008



Media Enquiries:

Jamie Lacey, (MedImmune)  [phone]

Steve Brown,  [phone]  (24 hours)

Edel McCaffrey,  [phone]  (24 hours)



Investor Enquiries:

Jonathan Hunt,  [phone]

Ed Seage,  [phone]

Karl Hard,  [phone]

Jorgen Winroth,  [phone]

Peter Vozzo, (MedImmune)  [phone]





                                    - Ends -


                      This information is provided by RNS
            The company news service from the London Stock Exchange